Remy Peptides · For in-vitro laboratory research only. Not for human or veterinary use.Research Use Only
Compound Cluster · Last checked May 28, 2026

Retatrutide Research Hub: Trials & Dosing

Retatrutide is Lilly's once-weekly triple agonist (GLP-1 + GIP + glucagon), still investigational in 2026. This hub points to the page that answers your question: dose math, pen handling, approval status, or UAE sourcing.

Pages
16 retatrutide pages across dosing, approval, and regional context
Clinical stage
Phase 3 — TRIUMPH-1 pivotal obesity readout May 21, 2026 (28.3% at 80 wks; 30.3% at 104 wks); TRIUMPH-2/-3 expected later in 2026
Compliance
For in-vitro laboratory research only. Not for human or veterinary use.

Quick answer — retatrutide research formats (mg per click, 300-click pens)

Start here for UAE & Google-style questions

This hub indexes trials, dosing, and approval pages. For one-pass answers to common UAE retatrutide questions—price, formats, delivery, legality—use the dedicated answer map on the Dubai guide, not scattered paragraphs across the cluster.

Where are the canonical UAE retatrutide answers?

Direct answer: Open the Retatrutide Dubai guide — direct answers for eight extractable blocks: what retatrutide is, trial side effects, vs semaglutide, Dubai price, where to buy in the UAE, six formats with batch purity, Abu Dhabi/Sharjah delivery, and UAE legality. Supplier checklist: buy retatrutide Dubai guide. Live formats and checkout: Retatrutide UAE verified route. For in-vitro laboratory research only under MoHAP Circular 17/2022.

Formats-only catalog: #retatrutide-uae-formats · commercial table: Retatrutide UAE formats · pricing: #pricing · COA: #verification.

Pick the right page for your question

The main Research Hub indexes every compound. This page is narrower — just retatrutide. Four common starting points:

Latest readout · May 21, 2026

TRIUMPH-1 pivotal obesity topline

28.3% mean weight loss at 80 weeks on 12 mg (n=2,339), rising to 30.3% at 104 weeks in a BMI ≥35 extension. 45.3% of 12 mg participants reached ≥30% weight loss, 65.3% fell below BMI 30. Dose-by-dose AE-driven discontinuation 4.1% / 6.9% / 11.3% vs 4.9% on placebo; dysesthesia up to 12.5% on 12 mg; UTIs noted. Full data: 86th ADA Scientific Sessions, June 2026. Sources: Lilly, TCTMD, AJMC. Full tracker: TRIUMPH trial tracker.

Status snapshot

Phase 3, still investigational

Reviewed May 28, 2026. Lilly reported pivotal TRIUMPH-1 obesity topline results on May 21, 2026 (28.3% mean weight loss at 80 weeks; 30.3% at 104 weeks in the BMI ≥35 extension), on top of the March 19, 2026 TRANSCEND-T2D-1 release. The pipeline page lists retatrutide Phase 3 across obesity, T2D, knee OA, OSA, low back pain, CV/renal outcomes, and MASLD/MASH; TRIUMPH-2 and TRIUMPH-3 readouts are expected later in 2026. No NDA filed.

Commercial outlook

FDA filing 2026, launch ~2027

Alongside the May 21 readout, a Lilly executive said the company hopes to launch the drug around 2027, with a regulatory submission expected in 2026. Separately, Lilly’s $4.5 billion additional Indiana manufacturing investment (May 6, 2026) expands capacity supporting its obesity and incretin pipeline — which includes retatrutide — rather than naming any single molecule. Sources: CNBC, PR Newswire.

Reference format

30 mg pen, 300 clicks

The Remy reference is the 30 mg pen: 300 clicks at 0.1 mg per click, batch RETP002, Janoshik HPLC at 99.262%. Handling on the pen guide, click math on the clicks chart.

Trust layer

Proof and provenance

COA Library, Brand Facts, Editorial Policy, Research Standards, and Contact Verification — the documents behind every claim on these pages.

Section 01

Start here

Six entry points covering the most common retatrutide questions.

Section 02

Fast facts

The headline answers, in case you don't need the deeper page.

Molecule

Lilly's triple agonist

Retatrutide (LY-3437943) is a once-weekly investigational peptide that activates GIP, GLP-1, and glucagon receptors in one compound. Full mechanism on the Retatrutide Profile.

EntityProfile
Status

Phase 3, not approved

Pivotal TRIUMPH-1 obesity topline reported May 21, 2026 (28.3% at 80 wks; 30.3% at 104 wks in BMI ≥35 extension); investigational status unchanged. The pipeline page keeps retatrutide Phase 3, with TRIUMPH-2 and TRIUMPH-3 readouts expected later in 2026. No NDA filed.

Reviewed May 25, 2026Approval page
Dosing

Three pages, three jobs

Dosage Guide for the titration ladder. Pen Clicks Guide for mg-to-click math. Pen Guide for storage, priming, and device handling.

RoutingPick by intent
Regional

UAE and Saudi are different questions

The UAE pages cover research-use availability, COAs, and supplier verification. The Saudi page is about status interpretation and the approved-product boundary. Use the page that matches your geography.

MarketPick by region
May 2026 Research Update — Cardiology in Review CKM Monograph

A narrative review in Cardiology in Review (Pillai et al, May 11, 2026) re-synthesised retatrutide’s Phase 2 dataset through the lens of cardiovascular-kidney-metabolic (CKM) disease. Key data points: 24.2% mean weight loss at 12 mg over 48 weeks with 63% achieving ≥20% loss; HbA1c −2.02% in T2D with 27% reaching normoglycaemia; DEXA showed 23.2% fat-mass reduction (comparable to bariatric surgery); 82.4% relative reduction in hepatic fat, with liver-fat normalisation in 86%; SBP −8.79 mmHg; significant attenuation of urine albumin-to-creatinine ratio. The review positions retatrutide as a multi-organ CKM agent rather than a weight-loss-only compound.

Section 03

Compound and protocol pages

Mechanism, dosing, safety, and head-to-head comparisons.

Section 04

Handling and dose tools

Pen mechanics, click math, storage, and the calculator.

Section 05

Approval status and regional sourcing

Filing status, trial milestones, and UAE / Saudi context.

Section 06

Retatrutide research FAQ

Direct answers to the most common retatrutide questions, with deeper pages linked from each.

What is retatrutide?

Retatrutide (LY-3437943) is Eli Lilly’s once-weekly investigational triple agonist that activates the GLP-1, GIP, and glucagon receptors in a single peptide. It is in Phase 3 clinical development across obesity, type 2 diabetes, knee osteoarthritis, OSA, low back pain, CV/renal outcomes, and MASLD/MASH. Full mechanism on the retatrutide profile.

Is retatrutide approved in 2026?

No. As of May 28, 2026, retatrutide is investigational — not approved by the FDA, EMA, or UAE MoHAP, and no NDA has been filed. Lilly reported positive TRIUMPH-1 pivotal obesity topline on May 21, 2026 (28.3% mean weight loss at 80 weeks on 12 mg). Full status: is retatrutide approved?

How many clicks per mg on the 30 mg retatrutide pen?

The 30 mg pen contains 300 clicks at 0.1 mg per click, so 1 mg = 10 clicks, 2 mg = 20 clicks, 4 mg = 40 clicks, 8 mg = 80 clicks, 12 mg = 120 clicks. The dial caps at 60 clicks (6 mg) per dispensing cycle, so targets above 6 mg require more than one dial turn. Full lookup: retatrutide pen clicks guide.

How is retatrutide dosed in Phase 3 trials?

The TRIUMPH and TRANSCEND programmes start at 2 mg once weekly and titrate every 4 weeks, escalating to 4 mg, 8 mg, or 12 mg maintenance arms depending on the trial. Full ladder on the retatrutide dosage guide; direct answers on the dosage FAQ.

What did TRIUMPH-1 show?

Lilly’s May 21, 2026 topline reported 28.3% mean weight loss at 80 weeks on the 12 mg arm (n=2,339), rising to 30.3% at 104 weeks in a BMI ≥35 extension. 45.3% of 12 mg participants reached ≥30% weight loss and 65.3% fell below BMI 30. AE-driven discontinuation was 4.1% / 6.9% / 11.3% across dose arms vs 4.9% on placebo. Full data: 86th ADA Scientific Sessions, June 2026. Tracker: TRIUMPH trial tracker.

Where can retatrutide be sourced in Dubai?

Retatrutide is not available through UAE pharmacies because it is not approved by MoHAP. Research-use supply is available through verified suppliers under UAE MoHAP Circular 17/2022. Format options and pricing are on the retatrutide in Dubai page, and the supplier verification checklist covers COA checks and channel verification.

How does retatrutide compare to tirzepatide?

Tirzepatide is a dual GIP/GLP-1 agonist already approved as Mounjaro and Zepbound. Retatrutide adds a third receptor (glucagon) and has shown larger Phase 2/3 weight loss numbers (24.2% mean at 12 mg / 48 weeks Phase 2; 28.3% at 80 weeks TRIUMPH-1) versus tirzepatide’s 22.5% at 72 weeks. Full comparison: retatrutide vs tirzepatide vs CagriSema.

What is retatrutide’s half-life and dosing cadence?

Retatrutide has an extended half-life supporting once-weekly subcutaneous administration in clinical trials. Steady-state accumulation and washout details are on the retatrutide half-life page.

Section 07

Primary sources

The official documents this hub's status reading is built on.

Official sources

  • Eli Lilly, May 21, 2026 — positive TRIUMPH-1 Phase 3 pivotal obesity topline (28.3% at 80 weeks; 30.3% at 104 weeks in the BMI ≥35 extension).
  • TCTMD, May 2026 — TRIUMPH-1 coverage with dose-by-dose efficacy and safety detail.
  • AJMC, May 2026 — TRIUMPH-1 30.3% extension data summary.
  • Eli Lilly, March 19, 2026 — positive TRANSCEND-T2D-1 Phase 3 topline. Retatrutide labelled investigational.
  • Eli Lilly, December 11, 2025 — positive TRIUMPH-4 Phase 3 topline (obesity with knee osteoarthritis).
  • Eli Lilly pipeline page — Phase 3 across obesity, T2D, knee OA, OSA, low back pain, CV/renal outcomes, and MASLD/MASH.
  • ClinicalTrials.gov NCT05929066 and NCT05882045 — active public records for TRIUMPH-1 and TRIUMPH-3.
  • Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. PMID 37366315. doi.org/10.1056/NEJMoa2301972 · NCT04881760 — primary peer-reviewed source for the 24.2% mean weight reduction at 48 weeks (12 mg) Phase 2 obesity figure.
  • Pillai AA, Frishman WH, Aronow WS, et al. Retatrutide as a triple-agonist for cardiovascular-kidney-metabolic syndrome. Cardiol Rev. 2026 May 11. PMID 42108533. pubmed.ncbi.nlm.nih.gov
  • CNBC, May 21, 2026 — Lilly executive guidance: regulatory submission expected 2026, hoped launch ~2027.
  • PR Newswire, May 6, 2026 — Lilly $4.5B additional Indiana manufacturing investment supporting the obesity/incretin pipeline.
How to read this

Status before market

If a page mixes approval language with retatrutide, check the approval and trial pages first. Local availability and supplier claims sit downstream of regulatory status, not in place of it.

Why a hub

One molecule, several questions

Retatrutide questions split across mechanism, dosing, approval timing, and regional sourcing. This page keeps the routes to each in one place.